Free Trial

Encompass Health (EHC) Competitors

$86.11
+0.66 (+0.77%)
(As of 04:26 PM ET)

EHC vs. SEM, CHE, GMED, ELAN, BIO, ROIV, HSIC, PEN, LEGN, and VKTX

Should you be buying Encompass Health stock or one of its competitors? The main competitors of Encompass Health include Select Medical (SEM), Chemed (CHE), Globus Medical (GMED), Elanco Animal Health (ELAN), Bio-Rad Laboratories (BIO), Roivant Sciences (ROIV), Henry Schein (HSIC), Penumbra (PEN), Legend Biotech (LEGN), and Viking Therapeutics (VKTX). These companies are all part of the "medical" sector.

Encompass Health vs.

Select Medical (NYSE:SEM) and Encompass Health (NYSE:EHC) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.

Select Medical has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Encompass Health has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

In the previous week, Select Medical had 2 more articles in the media than Encompass Health. MarketBeat recorded 10 mentions for Select Medical and 8 mentions for Encompass Health. Select Medical's average media sentiment score of 1.13 beat Encompass Health's score of 0.38 indicating that Encompass Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Select Medical
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Encompass Health
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

89.5% of Select Medical shares are held by institutional investors. Comparatively, 97.3% of Encompass Health shares are held by institutional investors. 17.5% of Select Medical shares are held by insiders. Comparatively, 2.1% of Encompass Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Select Medical currently has a consensus target price of $34.25, suggesting a potential upside of 1.21%. Encompass Health has a consensus target price of $90.29, suggesting a potential upside of 4.85%. Given Select Medical's stronger consensus rating and higher possible upside, analysts clearly believe Encompass Health is more favorable than Select Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Select Medical
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Encompass Health
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

Select Medical pays an annual dividend of $0.50 per share and has a dividend yield of 1.5%. Encompass Health pays an annual dividend of $0.60 per share and has a dividend yield of 0.7%. Select Medical pays out 23.8% of its earnings in the form of a dividend. Encompass Health pays out 16.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Encompass Health received 159 more outperform votes than Select Medical when rated by MarketBeat users. Likewise, 71.83% of users gave Encompass Health an outperform vote while only 57.85% of users gave Select Medical an outperform vote.

CompanyUnderperformOutperform
Select MedicalOutperform Votes
328
57.85%
Underperform Votes
239
42.15%
Encompass HealthOutperform Votes
487
71.83%
Underperform Votes
191
28.17%

Encompass Health has lower revenue, but higher earnings than Select Medical. Select Medical is trading at a lower price-to-earnings ratio than Encompass Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Select Medical$6.66B0.66$243.49M$2.1016.10
Encompass Health$4.96B1.75$352M$3.7023.27

Encompass Health has a net margin of 7.60% compared to Encompass Health's net margin of 3.97%. Encompass Health's return on equity of 18.11% beat Select Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Select Medical3.97% 18.11% 3.64%
Encompass Health 7.60%18.01%6.55%

Summary

Encompass Health beats Select Medical on 15 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EHC vs. The Competition

MetricEncompass HealthHospitals IndustryMedical SectorNYSE Exchange
Market Cap$8.67B$4.56B$4.96B$17.92B
Dividend Yield0.70%1.09%45.28%3.43%
P/E Ratio23.2713.05135.4124.26
Price / Sales1.750.912,474.5210.86
Price / Cash13.129.1432.4615.96
Price / Book3.832.465.005.05
Net Income$352M$178.36M$102.14M$973.44M
7 Day Performance-0.10%-4.09%2.39%1.99%
1 Month Performance8.70%5.42%6.26%6.93%
1 Year Performance39.34%4.21%8.67%24.22%

Encompass Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SEM
Select Medical
4.6826 of 5 stars
$34.08
+1.1%
$34.25
+0.5%
+19.1%$4.43B$6.66B16.2354,600Analyst Revision
CHE
Chemed
4.9728 of 5 stars
$568.76
0.0%
$681.00
+19.7%
+5.0%$8.61B$2.26B30.6115,087Insider Selling
Positive News
GMED
Globus Medical
4.5004 of 5 stars
$62.87
-1.4%
$66.50
+5.8%
+14.7%$8.51B$1.57B98.245,000Analyst Upgrade
Gap Up
ELAN
Elanco Animal Health
2.8763 of 5 stars
$17.07
+0.4%
$18.29
+7.1%
+102.0%$8.44B$4.42B-6.449,300
BIO
Bio-Rad Laboratories
4.7008 of 5 stars
$294.05
+3.0%
$461.00
+56.8%
-23.1%$8.39B$2.67B-28.388,030
ROIV
Roivant Sciences
2.4596 of 5 stars
$11.33
+1.3%
$16.90
+49.2%
+20.5%$9.13B$61.28M2.18904Positive News
HSIC
Henry Schein
4.5487 of 5 stars
$72.77
-0.5%
$81.73
+12.3%
-3.0%$9.35B$12.34B24.5825,000Positive News
PEN
Penumbra
4.8796 of 5 stars
$208.73
+1.9%
$300.64
+44.0%
-35.9%$8.09B$1.06B88.074,200
LEGN
Legend Biotech
2.6002 of 5 stars
$44.38
+3.3%
$82.64
+86.2%
-35.2%$8.07B$285.14M-29.991,800Earnings Report
VKTX
Viking Therapeutics
4.4152 of 5 stars
$72.50
+0.2%
$112.25
+54.8%
+191.7%$7.99BN/A-77.9628Analyst Upgrade

Related Companies and Tools

This page (NYSE:EHC) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners